Immunovant, INC. (IMVT) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Dec 12, 2025
• Immunovant Files 8-K: Unspecified Event Reported — Dec 11, 2025 Risk: medium
  Immunovant, Inc. filed an 8-K on December 11, 2025, reporting an "Other Event" that occurred on December 10, 2025. The filing does not disclose specific details
• Immunovant Reports Leadership and Compensation Changes — Nov 21, 2025 Risk: medium
  Immunovant, Inc. filed an 8-K on November 21, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of c
• Immunovant Files 8-K on Financials — Nov 10, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits
• Immunovant Files 8-K — Sep 3, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on September 3, 2025, reporting on other events and financial statements. The filing does not contain specific material events or
• Immunovant Files 8-K on Shareholder Vote Matters — Aug 28, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on August 28, 2025, reporting on a submission of matters to a vote of security holders that occurred on August 27, 2025. The compa
• Immunovant Appoints New Director and CMO — Jul 29, 2025 Risk: medium
  Immunovant, Inc. announced on July 28, 2025, the departure of director Dr. David M. Roth and the election of Dr. Amy J. Peterson as a new director. The company
• Immunovant Announces Board Changes and New CLO — Apr 21, 2025 Risk: medium
  Immunovant, Inc. announced on April 18, 2025, a series of significant corporate actions. These include the departure of director Dr. David M. Roth, the election
• Immunovant Files 8-K: Regulatory, Other Events & Exhibits — Mar 19, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on March 19, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events
• Immunovant, Inc. Files 8-K — Jan 24, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 24, 2025, reporting other events and financial statements. The company, formerly known as Health Sciences Acquisitions
• Immunovant Files 8-K for Regulatory Disclosure — Jan 14, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• Immunovant Files 8-K: Material Agreements & Equity Sales — Jan 13, 2025 Risk: low
  Immunovant, Inc. filed an 8-K on January 13, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and Regulation FD disc
• Immunovant Files 8-K with Regulatory Updates — Sep 9, 2024 Risk: low
  Immunovant, Inc. filed an 8-K on September 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other eve
• Immunovant Files 8-K on Shareholder Vote Matters — Aug 13, 2024 Risk: low
  Immunovant, Inc. filed an 8-K on August 13, 2024, reporting on matters submitted to a vote of security holders on August 12, 2024. The filing details the compan
• Immunovant Files 8-K for Regulation FD Disclosure on Jan 9, 2024 — Jan 9, 2024
  Immunovant, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This filing, under

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX